 ROCKVILLE, MD, May 19, 2021 GLOBE NEWSWIRE -- MacroGenics, Inc. NASDAQ: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from the Companys ongoing Phase 1 clinical trial of MGC018. This investigational antibody-drug conjugate ADC was designed to deliver a DNA alkylating duocarmycin payload to both dividing and non-dividing cells in a B7-H3-dependent manner. The dataset will be presented in a poster titled Phase 1 Dose Escalation Study of MGC018, an anti-B7-H3 Antibody-Drug Conjugate ADC, In Patients with Advanced Solid Tumors Abstract 2631 at the upcoming 2021 American Society of Clinical Oncology ASCO Annual Meeting to be held June 4-8, 2021. 